非小细胞肺癌市场按类型、治疗、最终用户和地区划分

2025 年全球非小细胞肺癌市场规模估计为 286.1 亿美元，预计到 2032 年将达到 543.8 亿美元，2025 年至 2032 年的复合年增长率为 9.6%。

数字。 2025 年非小细胞肺癌各地区市场占有率（%）

非小细胞肺癌（NSCLC）是最常见的肺癌类型，约占所有肺癌的85%。它是全球癌症死亡的主要原因之一。全球非小细胞肺癌市场的成长受到吸烟习惯和环境污染日益普遍、先进治疗方法研发活动活性化以及对标靶治疗和个性化治疗的需求不断增加等因素的推动。然而，高昂的治疗成本阻碍了市场的成长。

市场动态

全球非小细胞肺癌市场的成长受到已开发国家和新兴国家吸烟率上升、环境污染程度加剧以及人口老化的推动。根据世界卫生组织统计，全球每年报告约180万新发肺癌病例，其中大多数为非小细胞肺癌。标靶治疗和癌症治疗方法的进步为市场相关人员提供了机会。然而，标靶治疗的高成本以及低收入国家缺乏认知阻碍了市场的成长。此外，药物在测试中失败的风险也会对研发活动产生负面影响。

研究的主要特点

• 本报告对全球非小细胞肺癌市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、业绩和策略等参数，介绍了全球非小细胞肺癌市场的主要企业概况。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球非小细胞肺癌市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球非小细胞肺癌市场分析中使用的各种策略矩阵来促进他们的决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球非小细胞肺癌市场-冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020 年至 2032 年全球非小细胞肺癌市场（按类型划分）（十亿美元）

• 介绍
• 腺癌
• 鳞状细胞癌
• 大细胞癌
• 大细胞神经内分泌肿瘤

6. 2020 年至 2032 年全球非小细胞肺癌市场（依治疗方法划分）（十亿美元）

• 介绍
• 化疗
• 标靶治疗
• Bevacizumab（Avastin）
• 奈妥木单抗（Portrazza）
• Ramucirumab（CYRAMZA）
• 免疫疗法
• Nivolumab（Opdivo）
• Atezolizumab（TECENTRIQ）
• 其他的

7. 2020 年至 2032 年全球非小细胞肺癌市场（按最终用户划分）（十亿美元）

• 介绍
• 医院
• 居家医疗
• 专科门诊
• 其他的

8. 2020 年至 2032 年全球非小细胞肺癌市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • F. Hoffmann-La Roche Ltd
  • Honeywell International Inc.
  • AstraZeneca PLC
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 章节

• 参考
• 调查方法

Global Non-Small Cell Lung Cancer Market is estimated to be valued at USD 28.61 Bn in 2025 and is expected to reach USD 54.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2025

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics:

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

Detailed Segmentation-

• By Type
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors
• Treatment
  • Chemotherapy
  • Targeted Therapy
  • Bevacizumab
  • Necitumumab
  • Ramucirumab
  • Immunotherapy
  • Nivolumab
  • Atezolizumab
  • Others
• End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hoffmann-La Roche Ltd
  • Honeywell International Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Non-Small Cell Lung Cancer Market, By Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Adenocarcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Squamous Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Neuroendocrine Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Non-Small Cell Lung Cancer Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Care
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Non-Small Cell Lung Cancer Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Honeywell International Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Section

• References
• Research Methodology
• About Us and Sales Contact

"